Ascendis Pharma A (ASND) Cash from Financing Activities (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Cash from Financing Activities data on file, last reported at -$43.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 127.45% year-over-year to -$43.1 million; the trailing twelve-month figure through Mar 2026 stood at $42.1 million (down 90.61% YoY), and the FY2025 full-year result was $64.3 million, down 86.62% from the prior year.
• Cash from Financing Activities eased to -$43.1 million in Q1 2026, from $31.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $469.9 million in Q3 2024 to a low of -$43.1 million in Q1 2026.
• A 5-year average of $64.8 million and a median of $92967.8 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 1850254.95% in 2022 and plunged 573.35% in 2023, its largest moves.
• Tracing ASND's Cash from Financing Activities over 5 years: stood at $1.4 million in 2022, then sank by 573.35% to -$6.5 million in 2023, then jumped by 101.43% to $92967.8 in 2024, then jumped by 34212.36% to $31.9 million in 2025, then slumped by 235.18% to -$43.1 million in 2026.
• Business Quant data shows ASND's Cash from Financing Activities at -$43.1 million in Q1 2026, $31.9 million in Q4 2025, and $45.4 million in Q3 2025.